Back to Journals » Virus Adaptation and Treatment » Volume 3

Evolution and adaptation of the pandemic A/H1N1 2009 influenza virus

Authors Ducatez MF, Fabrizio TP, Webby RJ

Published 20 July 2011 Volume 2011:3 Pages 45—53

DOI https://doi.org/10.2147/VAAT.S9656

Review by Single-blind

Peer reviewer comments 3

Mariette F Ducatez, Thomas P Fabrizio, Richard J Webby
Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN, USA

Abstract: The emergence of the 2009 H1N1 pandemic influenza virus [A(H1N1)pdm09] has provided the public health community with many challenges, but also the scientific community with an opportunity to monitor closely its evolution through the processes of drift and shift. To date, and despite having circulated in humans for nearly two years, little antigenic variation has been observed in the A(H1N1)pdm09 viruses. However, as the A(H1N1)pdm09 virus continues to circulate and the immunologic pressure within the human population increases, future antigenic change is almost a certainty. Several coinfections of A(H1N1)pdm09 and seasonal A(H1N1) or A(H3N2) viruses have been observed, but no reassortant viruses have been described in humans, suggesting a lack of fitness of reassortant viruses or a lack of opportunities for interaction of different viral lineages. In contrast, multiple reassortment events have been detected in swine populations between A(H1N1) pdm09 and other endemic swine viruses. Somewhat surprisingly, many of the well characterized influenza virus virulence markers appear to have limited impact on the phenotype of the A(H1N1)pdm09 viruses when they have been introduced into mutant viruses in laboratory settings. As such, it is unclear what the evolutionary path of the pandemic virus will be, but the monitoring of any changes in the circulating viruses will remain a global public and animal health priority.

Keywords: influenza, pandemic, evolution, adaptation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Hematuria following Botox treatment for upper limb spasticity: a case report

Lo TC, Yeung ST, Lee S, Chang EY

Journal of Pain Research 2015, 8:619-622

Published Date: 14 September 2015

Mechanisms underlying probucol-induced hERG-channel deficiency

Shi YQ, Yan CC, Zhang X, Yan M, Liu LR, Geng HZ, Lv L, Li BX

Drug Design, Development and Therapy 2015, 9:3695-3704

Published Date: 20 July 2015

Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries

Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M

Patient Preference and Adherence 2014, 8:1713-1720

Published Date: 12 December 2014

The Yamaguchi fox/pigeon-imitation test, a brief cognitive performance rating tool, in a community-dwelling population: normative data for Japanese subjects – a preliminary study

Ishioka M, Sugawara N, Kaneda A, Okubo N, Iwane K, Takahashi I, Yasui-Furukori N

Neuropsychiatric Disease and Treatment 2014, 10:1721-1725

Published Date: 11 September 2014

Towards Horizon 2020: challenges and advances for clinical mental health research – outcome of an expert survey

van der Feltz-Cornelis CM, van Os J, Knappe S, Schumann G, Vieta E, Wittchen HU, Lewis SW, Elfeddali I, Wahlbeck K, Linszen D, Obradors-Tarragó C, Haro JM

Neuropsychiatric Disease and Treatment 2014, 10:1057-1068

Published Date: 27 June 2014

Managing hemophilia: the role of mobile technology

Khair K, Holland M

Smart Homecare Technology and TeleHealth 2014, 2:39-44

Published Date: 6 May 2014

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

International Journal of Nanomedicine 2010, 5:581-591

Published Date: 6 August 2010